Michael Okunewitch

Michael Okunewitch is an Equity Research Associate specializing in the biotechnology sector at Maxim Group, where he has been employed since 2017. He holds a degree from Stony Brook University, which he completed in the same year he joined Maxim Group. His role primarily involves analyzing stocks within the healthcare sector, focusing on biotechnology companies.

Professional Background

• Position: Equity Research Associate - Biotech at Maxim Group
• Experience: Joined Maxim Group in 2017
• Education: Bachelor's degree from Stony Brook University

Analyst Performance

Okunewitch has documented a total of 10 price targets and ratings across four stocks, with a notable performance where 80% of his ratings are classified as "Buy" and 20% as "Hold." His most successful recommendation was for Kiora Pharmaceuticals (KPRX), where he projected significant upside potential.12 His overall success rate stands at approximately 34%, with an average return of -12.90% per transaction.23

Notable Achievements

• Best-performing stock recommendation: Lexaria Bioscience Corp. (LEXX), which yielded a return of +350.60% from August 2023 to August 2024.2
• Active coverage of various biotech stocks, including KPRX and others in the healthcare sector.12

Okunewitch's analytical insights are valuable for investors looking to navigate the complexities of the biotech market, leveraging his academic background and professional experience to inform stock recommendations.